Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Clovis Oncology Inc (CLVS)’s Ovarian Cancer Drug Faces Stiff Competition From AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO)

Trials of rival drugs from AstraZeneca PLC (ADR) (NYSE:AZN) and TESARO Inc (NASDAQ:TSRO) will determine the adoption of the PARP inhibitor, Rubraca from Clovis Oncology Inc (NASDAQ:CLVS).

According to Debjit Chattopadhyay, a Janney analyst, trials from AstraZeneca and Tesaro are likely to change the role of PARP inhibitors from being second to front-line treatments. This will result in a reduction of the pool of Rubraca patients.

biotech, shares, market, amgen, percent, technical, economy, pharmaceutical, rate, quote, producer, drag, business, bio, capitalization, tech, biotechnology, sector, gain,,

g0d4ather/Shutterstock.com

At the moment AstraZeneca PLC (ADR) (NYSE:AZN) and TESARO Inc (NASDAQ:TSRO) are in the process of testing PARP (Poly ADP ribose polymerase) to establish whether or not the enzymes could offer any help in the treatment of ovarian and other cancers.

Many More Trials Are In Waiting

There seems to be much more into Rubraca’s adoption. Chattopadhyay says that the adoption may also be affected by AstraZeneca PLC (ADR) (NYSE:AZN)’s SOLO-2 trial as well as TESARO Inc (NASDAQ:TSRO)’s PRIMA. However, there was a notable progression of PARP inhibitor niraparib from an earlier phase three trial from Tesaro, commonly known as NOVA.

Nonetheless, Chattopadhyay says, “If SOLO-2 is not in the same ballpark as NOVA, questions on interchangeability of PARPs could impact Clovis shares heading into ARIEL-3 readout.”

For ARIEL-3, Rubraca is a maintenance treatment, which is commonly used in patients with an ovarian fallopian tube.

Follow Astrazeneca Plc (NYSE:AZN)
Trade (NYSE:AZN) Now!

Clovis Oncology Inc (NASDAQ:CLVS) stock fell 1.1% to $61.83. However, this year has had a 40% run so far. Chattopadhyay acknowledges that Clovis shares have been doing well since early-November, classifying the rise as “too far, too fast.”

Follow Tesaro Inc. (NASDAQ:TSRO)
Trade (NASDAQ:TSRO) Now!

Clearly, there has been a neck-and-neck race between the Clovis drug, which was approved in December and Tesaro’s New Drug Application for an ovarian cancer drug. This won priority review a day after the Clovis Oncology Inc (NASDAQ:CLVS) approval. At the same time, there have been important plans for acquisitions. For $5.2 billion, Takeda Pharmaceuticals is planning to acquire Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) as well as Merrimack Pharmaceuticals Inc (NASDAQ:MACK)’s $575 million divestiture from an oncology asset.

Follow Clovis Oncology Inc. (NASDAQ:CLVS)
Trade (NASDAQ:CLVS) Now!

Note: This article is written by Adam Russell and originally published at Market Exclusive.